Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
97%
Chronic Hepatitis B
62%
Hepatitis B Virus
32%
Tenofovir
21%
Adefovir
21%
Entecavir
20%
Combination Therapy
19%
Antivirus Agent
17%
Lamivudine
16%
Liver Cirrhosis
16%
Infection
14%
Overall Survival
13%
Telbivudine
12%
Neoplasm
12%
Somatomedin C
11%
Polyacrylamide Gel Electrophoresis
11%
Tenofovir Disoproxil
10%
Phosphotransferase
9%
Malignant Neoplasm
9%
Sorafenib
9%
Recurrent Disease
8%
Hepatitis B
8%
Fibrosis
8%
Nonalcoholic Fatty Liver
7%
Fatty Liver
7%
Bacterial Peritonitis
7%
Alcohol Liver Cirrhosis
7%
Portal Vein Thrombosis
7%
Anticarcinogen
7%
Hepatitis B(e) Antigen
7%
Virus DNA
7%
Liver Cancer
7%
Liver Fibrosis
6%
Cardiovascular Disease
6%
Monotherapy
5%
Antiviral Therapy
5%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Chronic Hepatitis B
39%
Hepatitis B Virus
18%
Liver Cirrhosis
16%
Nonalcoholic Fatty Liver
15%
Overall Survival
14%
Hazard Ratio
13%
Transcatheter Arterial Chemoembolization
13%
Liver Fibrosis
13%
Polyacrylamide Gel Electrophoresis
11%
Neoplasm
11%
Fibrosis
11%
Entecavir
10%
Antiviral Therapy
10%
Liver Cancer
9%
Surgery
9%
Recurrent Disease
9%
Chronic Liver Failure
8%
Bilirubin
7%
SOFA Score
7%
Drug Therapy
7%
Alcohol Liver Disease
7%
Physical Activity
7%
Chronic Hepatitis
7%
Fluorodeoxyglucose F 18
7%
Spontaneous Bacterial Peritonitis
7%
Portal Vein Thrombosis
7%
Non-Alcoholic Fatty Liver Disease
7%
Survival Estimate
7%
Colorectal Carcinoma
7%
Antivirus Agent
7%
Lamivudine
7%
Cardiovascular Disease
6%
Virus Reactivation
6%
Tenofovir
6%
Infection
5%
Positron Emission Tomography-Computed Tomography
5%
Computer Assisted Tomography
5%
Risk Stratification
5%
Carcinoma Cell
5%
Metastatic Carcinoma
5%
Echography
5%
Hepatitis B
5%
Cohort Analysis
5%